Partex.AI

At the 𝟮𝗻𝗱 𝗔𝗻𝗻𝘂𝗮𝗹 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹𝘀 𝗦𝗲𝗿𝗶𝗲𝘀 𝟮𝟬𝟮𝟲 in Bengaluru, Partex.AI was proud to be a 𝗦𝗶𝗹𝘃𝗲𝗿 𝗣𝗮𝗿𝘁𝗻𝗲𝗿 of the event, with Holger Hoffmann, 𝗣𝗿𝗲𝘀𝗶𝗱𝗲𝗻𝘁 – 𝗜𝗻𝗱𝗶𝗮 & 𝗠𝗶𝗱𝗱𝗹𝗲 𝗘𝗮𝘀𝘁, Partex.AI, joining an important industry discussion as a panelist: “𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 𝗗𝗿𝗶𝘃𝗲𝗻 & 𝗡𝗲𝘅𝘁-𝗚𝗲𝗻 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹𝘀: 𝗟𝗲𝘃𝗲𝗿𝗮𝗴𝗶𝗻𝗴 𝗔𝗜, 𝗥𝗪𝗗 & 𝗗𝗶𝗴𝗶𝘁𝗮𝗹 𝗧𝗼𝗼𝗹𝘀 𝗳𝗼𝗿 𝗦𝗺𝗮𝗿𝘁𝗲𝗿 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵” The panel brought together: • Dr. Kavita Lamror - Former Partner, RWE & Digital Transformation, Maxis Clinical (Moderator) • Hitendra Nath Pandey - Director - Statistics, Eli Lilly and Company • Dr Pankaj Thakur PhD - Sr GM & Head Project Management, Hetero • Yoganand Kumar D. - Associate Director - Global Scientific Communications, Eli Lilly and Company • Dr.Priya Janardhana - Senior Manager, Medical Lead - Public Care & RWE, Novo Nordisk The discussion explored how 𝗔𝗜, 𝗿𝗲𝗮𝗹-𝘄𝗼𝗿𝗹𝗱 𝗱𝗮𝘁𝗮 (𝗥𝗪𝗗), 𝗮𝗻𝗱 𝗱𝗶𝗴𝗶𝘁𝗮𝗹 𝘁𝗼𝗼𝗹𝘀 𝗮𝗿𝗲 𝗲𝗻𝗮𝗯𝗹𝗶𝗻𝗴 𝘀𝗺𝗮𝗿𝘁𝗲𝗿, 𝗺𝗼𝗿𝗲 𝗰𝗼𝗻𝗻𝗲𝗰𝘁𝗲𝗱, 𝗮𝗻𝗱 𝗳𝘂𝘁𝘂𝗿𝗲-𝗿𝗲𝗮𝗱𝘆 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹 𝗮𝗽𝗽𝗿𝗼𝗮𝗰𝗵𝗲𝘀. As clinical research continues to evolve, the integration of technology, data, and industry expertise will play an increasingly important role in shaping more efficient and innovative approaches to clinical development. Thank you to Virtue Insight for bringing together leaders from across the clinical research ecosystem and creating a valuable platform for collaboration, knowledge sharing, and meaningful discussions around the future of clinical trials. #PartexAI #ClinicalTrials #AIinHealthcare #RealWorldData #DigitalHealth #LifeSciences #ClinicalResearch #HealthcareInnovation #Pharma

At the 通商中国 Business China - 𝗙𝘂𝘁𝘂𝗿𝗲𝗖𝗵𝗶𝗻𝗮 𝗚𝗹𝗼𝗯𝗮𝗹 𝗙𝗼𝗿𝘂𝗺 𝟮𝟬𝟮𝟲 in Singapore, Dr. Gunjan Bhardwaj, Founder & CEO, Partex.AI, joined an important discussion on this very question as a speaker and panelist: “𝗧𝗵𝗲 𝗦𝘁𝗮𝗸𝗲𝘀 𝗼𝗳 𝗦𝗰𝗮𝗹𝗲: 𝗔𝗜 𝗦𝗮𝗳𝗲𝘁𝘆 𝗮𝘀 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗜𝗺𝗽𝗲𝗿𝗮𝘁𝗶𝘃𝗲” The panel brought together:  • Mr. Ruimin He - Singapore Government Chief AI Officer, Ministry of Digital Development and Information  • Mr. hongjiang zhang - Distinguished Visiting Professor, Tsinghua University  • Mr. Boon Khee LiM - CIO Singapore, Head of IWPB Technology, Asia & Middle East, HSBC  • Moderator: Kaiser Kuo - Co-Founder & Host, Sinica Podcast The discussion highlighted an increasingly important reality: 𝗮𝘀 𝗔𝗜 𝗰𝗮𝗽𝗮𝗯𝗶𝗹𝗶𝘁𝗶𝗲𝘀 𝗮𝗱𝘃𝗮𝗻𝗰𝗲, 𝘁𝗵𝗲 𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝘁𝗼 𝗲𝘃𝗮𝗹𝘂𝗮𝘁𝗲, 𝗺𝗼𝗻𝗶𝘁𝗼𝗿, 𝘀𝗮𝗳𝗲𝗴𝘂𝗮𝗿𝗱 𝗮𝗻𝗱 𝗴𝗼𝘃𝗲𝗿𝗻 𝘁𝗵𝗲𝘀𝗲 𝘀𝘆𝘀𝘁𝗲𝗺𝘀 𝗻𝗲𝗲𝗱𝘀 𝘁𝗼 𝗮𝗱𝘃𝗮𝗻𝗰𝗲 𝗮𝗹𝗼𝗻𝗴𝘀𝗶𝗱𝗲 𝘁𝗵𝗲𝗺. For industries where AI is being applied to critical decisions and highly sensitive information, this becomes especially significant. The challenge is not simply enabling AI it is creating the conditions for 𝗔𝗜 𝘁𝗵𝗮𝘁 𝗰𝗮𝗻 𝗯𝗲 𝘁𝗿𝘂𝘀𝘁𝗲𝗱, 𝗺𝗼𝗻𝗶𝘁𝗼𝗿𝗲𝗱 𝗮𝗻𝗱 𝗿𝗲𝘀𝗽𝗼𝗻𝘀𝗶𝗯𝗹𝘆 𝗱𝗲𝗽𝗹𝗼𝘆𝗲𝗱 𝗮𝘁 𝘀𝗰𝗮𝗹𝗲. Thank you to 通商中国 Business China - 𝗙𝘂𝘁𝘂𝗿𝗲𝗖𝗵𝗶𝗻𝗮 𝗚𝗹𝗼𝗯𝗮𝗹 𝗙𝗼𝗿𝘂𝗺 𝗮𝗻𝗱 𝗕𝘂𝘀𝗶𝗻𝗲𝘀𝘀 𝗖𝗵𝗶𝗻𝗮 for bringing together such a diverse group of voices for this important dialogue. #PartexAI #FutureChinaGlobalForum #AI #AISafety #ResponsibleAI #AILeadership #AIInnovation #ArtificialIntelligence #Governance #Singapore

AI Safety Is Becoming a Strategic Imperative As AI moves rapidly from experimentation to deployment, the conversation around AI is evolving from 𝘄𝗵𝗮𝘁 𝗔𝗜 𝗰𝗮𝗻 𝗱𝗼 𝘁𝗼 𝗵𝗼𝘄 𝘄𝗲 𝗯𝘂𝗶𝗹𝗱 𝘁𝗵𝗲 𝘀𝘆𝘀𝘁𝗲𝗺𝘀, 𝘀𝗮𝗳𝗲𝗴𝘂𝗮𝗿𝗱𝘀 𝗮𝗻𝗱 𝗴𝗼𝘃𝗲𝗿𝗻𝗮𝗻𝗰𝗲 𝗻𝗲𝗲𝗱𝗲𝗱 𝘁𝗼 𝘂𝘀𝗲 𝗶𝘁 𝗿𝗲𝘀𝗽𝗼𝗻𝘀𝗶𝗯𝗹𝘆 𝗮𝘁 𝘀𝗰𝗮𝗹𝗲. At the 通商中国 Business China - 𝗙𝘂𝘁𝘂𝗿𝗲𝗖𝗵𝗶𝗻𝗮 𝗚𝗹𝗼𝗯𝗮𝗹 𝗙𝗼𝗿𝘂𝗺 𝟮𝟬𝟮𝟲 𝗶𝗻 𝗦𝗶𝗻𝗴𝗮𝗽𝗼𝗿𝗲, Dr. Gunjan Bhardwaj, Founder & CEO of Partex.AI, joined the conversation as a 𝘀𝗽𝗲𝗮𝗸𝗲𝗿 𝗮𝗻𝗱 𝗽𝗮𝗻𝗲𝗹𝗶𝘀𝘁 for: “𝗧𝗵𝗲 𝗦𝘁𝗮𝗸𝗲𝘀 𝗼𝗳 𝗦𝗰𝗮𝗹𝗲: 𝗔𝗜 𝗦𝗮𝗳𝗲𝘁𝘆 𝗮𝘀 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗜𝗺𝗽𝗲𝗿𝗮𝘁𝗶𝘃𝗲” The panel brought together perspectives on the growing importance of 𝗔𝗜 𝘀𝗮𝗳𝗲𝘁𝘆, 𝗮𝗰𝗰𝗼𝘂𝗻𝘁𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝗮𝗻𝗱 𝗴𝗼𝘃𝗲𝗿𝗻𝗮𝗻𝗰𝗲 as AI becomes increasingly embedded across industries and economies. For organisations adopting AI, scaling the technology also means addressing the questions that come with it:  • How do we build trust?  • How do we maintain accountability?  • And how do we ensure that AI systems create value while remaining responsible and aligned with the people and institutions they serve? At Partex.AI, we see these questions as integral to the journey from 𝗔𝗜 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝘁𝗼 𝗿𝗲𝗮𝗹-𝘄𝗼𝗿𝗹𝗱 𝗶𝗺𝗽𝗮𝗰𝘁 particularly in highly regulated and knowledge-intensive industries. Thank you to the 𝗙𝘂𝘁𝘂𝗿𝗲𝗖𝗵𝗶𝗻𝗮 𝗚𝗹𝗼𝗯𝗮𝗹 𝗙𝗼𝗿𝘂𝗺 for bringing together leaders from business, government, technology and academia for this important conversation. #PartexAI #FutureChinaGlobalForum #AI #AISafety #AI治理 #AILeadership #ResponsibleAI #AIInnovation #Technology #ArtificialIntelligence

𝗠𝗮𝗵𝗮𝗿𝗮𝘀𝗵𝘁𝗿𝗮–𝗛𝗲𝘀𝘀𝗲𝗻: 𝗕𝘂𝗶𝗹𝗱𝗶𝗻𝗴 𝗕𝗿𝗶𝗱𝗴𝗲𝘀 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 A glimpse into the 𝗠𝗮𝗵𝗮𝗿𝗮𝘀𝗵𝘁𝗿𝗮–𝗛𝗲𝘀𝘀𝗲𝗻 𝗘𝗰𝗼𝗻𝗼𝗺𝗶𝗰 & 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 𝗗𝗶𝗮𝗹𝗼𝗴𝘂𝗲, hosted by Partex.AI N.V. and NSE India in Mumbai on 20 August 2026. For Partex.AI, this was more than a dialogue it was an opportunity to 𝗯𝗿𝗶𝗻𝗴 𝘁𝗼𝗴𝗲𝘁𝗵𝗲𝗿 𝗹𝗲𝗮𝗱𝗲𝗿𝘀, 𝗯𝘂𝘀𝗶𝗻𝗲𝘀𝘀𝗲𝘀 𝗮𝗻𝗱 𝗶𝗻𝘀𝘁𝗶𝘁𝘂𝘁𝗶𝗼𝗻𝘀 𝗳𝗿𝗼𝗺 𝗠𝗮𝗵𝗮𝗿𝗮𝘀𝗵𝘁𝗿𝗮 𝗮𝗻𝗱 𝗛𝗲𝘀𝘀𝗲𝗻 to explore meaningful avenues for collaboration across technology, innovation, pharmaceuticals, finance, IT, investment, market access and talent. The presence of 𝗛𝗼𝗻’𝗯𝗹𝗲 𝗚𝗼𝘃𝗲𝗿𝗻𝗼𝗿 𝗼𝗳 𝗠𝗮𝗵𝗮𝗿𝗮𝘀𝗵𝘁𝗿𝗮 𝗦𝗵𝗿𝗶 𝗝𝗶𝘀𝗵𝗻𝘂 𝗗𝗲𝘃 𝗩𝗮𝗿𝗺𝗮, 𝗠𝗶𝗻𝗶𝘀𝘁𝗲𝗿 𝗣𝗿𝗲𝘀𝗶𝗱𝗲𝗻𝘁 𝗼𝗳 𝗛𝗲𝘀𝘀𝗲𝗻 Mr. Boris Rhein, State Minister Mr. Manfred Pentz, Dr. Gunjan Bhardwaj, Founder & CEO, Partex.AI, Mr. Gaurav Tripathi, Co-founder and CTO, Partex.AI and Mr. Ashish Chauhan, MD & CEO, NSE India, reflected the strength and significance of this India–Germany engagement. A key outcome of the visit was the signing of a 𝗝𝗼𝗶𝗻𝘁 𝗗𝗲𝗰𝗹𝗮𝗿𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗜𝗻𝘁𝗲𝗻𝘁 𝗳𝗼𝗿 𝗘𝗻𝗵𝗮𝗻𝗰𝗲𝗱 𝗘𝗰𝗼𝗻𝗼𝗺𝗶𝗰 𝗖𝗼𝗼𝗽𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝗯𝗲𝘁𝘄𝗲𝗲𝗻 𝗠𝗮𝗵𝗮𝗿𝗮𝘀𝗵𝘁𝗿𝗮 𝗮𝗻𝗱 𝗛𝗲𝘀𝘀𝗲𝗻, covering areas including investment, R&D, technological advancement, AI and skilled workforce mobility. At Partex.AI, we believe that 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 𝗯𝗲𝗰𝗼𝗺𝗲𝘀 𝘁𝗿𝘂𝗹𝘆 𝘁𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝘃𝗲 𝘄𝗵𝗲𝗻 𝗶𝘁 𝗰𝗼𝗻𝗻𝗲𝗰𝘁𝘀 𝗲𝗰𝗼𝘀𝘆𝘀𝘁𝗲𝗺𝘀, 𝗶𝗻𝘀𝘁𝗶𝘁𝘂𝘁𝗶𝗼𝗻𝘀 𝗮𝗻𝗱 𝗽𝗲𝗼𝗽𝗹𝗲. We are proud to have played a role in creating a platform for this exchange and look forward to seeing these conversations translate into 𝗱𝗲𝗲𝗽𝗲𝗿 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽𝘀 𝗮𝗻𝗱 𝗻𝗲𝘄 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀 𝗯𝗲𝘁𝘄𝗲𝗲𝗻 𝗠𝗮𝗵𝗮𝗿𝗮𝘀𝗵𝘁𝗿𝗮 𝗮𝗻𝗱 𝗛𝗲𝘀𝘀𝗲𝗻. #PartexAI #MaharashtraHessen #EconomicCooperation #Technology #Innovation #AI #Pharma #IndiaGermany #BusinessCollaboration #GlobalPartnerships

We’re pleased to share that Holger Hoffmann, President - India & Middle East, Partex.AI N.V., will be joining the 𝟮𝗻𝗱 𝗔𝗻𝗻𝘂𝗮𝗹 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹𝘀 𝗦𝗲𝗿𝗶𝗲𝘀 𝟮𝟬𝟮𝟲 as a speaker in Bengaluru. The conference brings together leaders across pharma, biotech, CROs, clinical research, regulatory affairs, and technology to discuss the evolving clinical trials landscape including 𝗔𝗜 𝗮𝗻𝗱 𝗱𝗶𝗴𝗶𝘁𝗮𝗹 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵, 𝗱𝗲𝗰𝗲𝗻𝘁𝗿𝗮𝗹𝗶𝘀𝗲𝗱 𝘁𝗿𝗶𝗮𝗹𝘀, 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗿𝗲𝗳𝗼𝗿𝗺𝘀, 𝗿𝗲𝗮𝗹-𝘄𝗼𝗿𝗹𝗱 𝗲𝘃𝗶𝗱𝗲𝗻𝗰𝗲, 𝗮𝗻𝗱 𝗽𝗮𝘁𝗶𝗲𝗻𝘁-𝗰𝗲𝗻𝘁𝗿𝗶𝗰 𝘁𝗿𝗶𝗮𝗹 𝗱𝗲𝘀𝗶𝗴𝗻. We look forward to Holger sharing his perspectives and engaging with fellow industry leaders on 𝗵𝗼𝘄 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 𝗮𝗻𝗱 𝗔𝗜 𝗰𝗮𝗻 𝗵𝗲𝗹𝗽 𝘀𝗵𝗮𝗽𝗲 𝗺𝗼𝗿𝗲 𝗲𝗳𝗳𝗶𝗰𝗶𝗲𝗻𝘁, 𝗱𝗮𝘁𝗮-𝗱𝗿𝗶𝘃𝗲𝗻 𝗮𝗻𝗱 𝗽𝗮𝘁𝗶𝗲𝗻𝘁-𝗰𝗲𝗻𝘁𝗿𝗶𝗰 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹𝘀. 📍 Bengaluru, India 📅 24 September 2026 #PartexAI #ClinicalTrials #ClinicalResearch #AIinHealthcare #LifeSciences #DrugDevelopment #Pharma #Biotech #HealthcareInnovation #Bengaluru

We are pleased to share that 𝗗𝗿. Gunjan Bhardwaj, Founder & CEO, Partex.AI, will be joining the 𝗙𝘂𝘁𝘂𝗿𝗲𝗖𝗵𝗶𝗻𝗮 𝗚𝗹𝗼𝗯𝗮𝗹 𝗙𝗼𝗿𝘂𝗺 𝟮𝟬𝟮𝟲 as a speaker and panelist in Singapore. The forum brings together leaders from business, government, technology and academia to discuss the forces shaping China, Asia and the global economy, with this year’s programme placing a strong focus on 𝗔𝗜, 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆, 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝘁𝗵𝗲 𝗳𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗿𝗲𝗴𝗶𝗼𝗻𝗮𝗹 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻. As AI moves from experimentation to real-world deployment, the conversation is increasingly shifting from 𝘄𝗵𝗮𝘁 𝗔𝗜 𝗰𝗮𝗻 𝗱𝗼 to 𝗵𝗼𝘄 𝗼𝗿𝗴𝗮𝗻𝗶𝘀𝗮𝘁𝗶𝗼𝗻𝘀 𝗰𝗮𝗻 𝘁𝗿𝗮𝗻𝘀𝗹𝗮𝘁𝗲 𝗔𝗜 𝗰𝗮𝗽𝗮𝗯𝗶𝗹𝗶𝘁𝗶𝗲𝘀 𝗶𝗻𝘁𝗼 𝗺𝗲𝗮𝗻𝗶𝗻𝗴𝗳𝘂𝗹 𝗼𝘂𝘁𝗰𝗼𝗺𝗲𝘀 𝗮𝘁 𝘀𝗰𝗮𝗹𝗲. 📍 Singapore 📅 24–25 September 2026 #PartexAI #FutureChinaGlobalForum #FCGF2026 #BusinessChina #ArtificialIntelligence #AI #Innovation #LifeSciences #Healthcare #Singapore

We’re pleased to be part of the 𝟱𝘁𝗵 Forbes Middle East 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗟𝗲𝗮𝗱𝗲𝗿𝘀 𝗦𝘂𝗺𝗺𝗶𝘁, taking place on September 22–23 in Abu Dhabi. Under the theme “𝗗𝗲𝗳𝗶𝗻𝗶𝗻𝗴 𝗚𝗹𝗼𝗯𝗮𝗹 𝗦𝘁𝗮𝗻𝗱𝗮𝗿𝗱𝘀 𝗶𝗻 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗘𝘅𝗰𝗲𝗹𝗹𝗲𝗻𝗰𝗲,” the summit brings together policymakers, healthcare leaders, scientists, and innovators to explore how technology, precision medicine, AI, and new models of care are shaping the future of healthcare. At Partex.AI, we are building at the intersection of 𝗔𝗜, 𝗹𝗶𝗳𝗲 𝘀𝗰𝗶𝗲𝗻𝗰𝗲𝘀, 𝗮𝗻𝗱 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲, with a focus on turning complex biomedical data into actionable intelligence from research and drug discovery to therapeutic development and commercialization. We look forward to connecting with healthcare and life sciences leaders from across the region and beyond, exchanging perspectives, and exploring opportunities to advance 𝗔𝗜-𝗽𝗼𝘄𝗲𝗿𝗲𝗱 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗶𝗻 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲. 📍 Emirates Palace Mandarin Oriental, Abu Dhabi 📅 September 22–23, 2026 #PartexAI #ForbesMiddleEast #HealthcareLeadersSummit #AbuDhabi #HealthcareInnovation #AIinHealthcare #LifeSciences #PrecisionMedicine #ArtificialIntelligence #FutureOfHealthcare

𝗙𝗿𝗼𝗺 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝘁𝗼 𝗽𝗿𝗲𝘃𝗲𝗻𝘁𝗶𝗼𝗻: 𝗔𝗜 𝗶𝘀 𝗿𝗲𝘀𝗵𝗮𝗽𝗶𝗻𝗴 𝘁𝗵𝗲 𝗳𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲. As healthcare systems evolve, the ability to understand disease earlier, learn from real-world patient outcomes, and continuously improve therapies is becoming increasingly important. At the Forbes Middle East 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗟𝗲𝗮𝗱𝗲𝗿𝘀 𝗦𝘂𝗺𝗺𝗶𝘁 𝗶𝗻 𝗥𝗶𝘆𝗮𝗱𝗵, Dr. Gunjan Bhardwaj, Founder & CEO of Partex.AI, shared his perspective on the role of real-world patient feedback in understanding how therapies perform after reaching the market. His comments were featured in Arab News in its latest article, “𝗔𝗜 𝗵𝗲𝗹𝗽𝘀 𝘀𝗵𝗶𝗳𝘁 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗳𝗿𝗼𝗺 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝘁𝗼 𝗽𝗿𝗲𝘃𝗲𝗻𝘁𝗶𝗼𝗻 𝗶𝗻 𝗞𝗶𝗻𝗴𝗱𝗼𝗺,” which explores how AI, genomics and data-sharing are contributing to a more predictive and preventive healthcare ecosystem in Saudi Arabia. For Partex.AI, this reflects an important shift: 𝘁𝗵𝗲 𝗷𝗼𝘂𝗿𝗻𝗲𝘆 𝗼𝗳 𝗮 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗱𝗼𝗲𝘀 𝗻𝗼𝘁 𝗲𝗻𝗱 𝘄𝗵𝗲𝗻 𝗶𝘁 𝗿𝗲𝗮𝗰𝗵𝗲𝘀 𝘁𝗵𝗲 𝗺𝗮𝗿𝗸𝗲𝘁. 𝗥𝗲𝗮𝗹-𝘄𝗼𝗿𝗹𝗱 𝗼𝘂𝘁𝗰𝗼𝗺𝗲𝘀 𝗰𝗮𝗻 𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗲 𝘃𝗮𝗹𝘂𝗮𝗯𝗹𝗲 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝘁𝗵𝗮𝘁 𝗵𝗲𝗹𝗽 𝘂𝘀 𝗯𝗲𝘁𝘁𝗲𝗿 𝘂𝗻𝗱𝗲𝗿𝘀𝘁𝗮𝗻𝗱 𝘄𝗵𝗮𝘁 𝘄𝗼𝗿𝗸𝘀, 𝗳𝗼𝗿 𝘄𝗵𝗼𝗺, 𝗮𝗻𝗱 𝘄𝗵𝗲𝗿𝗲 𝗶𝗺𝗽𝗿𝗼𝘃𝗲𝗺𝗲𝗻𝘁𝘀 𝗺𝗮𝘆 𝗯𝗲 𝗻𝗲𝗲𝗱𝗲𝗱. As Saudi Arabia continues to build its healthcare ecosystem, the opportunity to combine AI, data and real-world evidence offers new possibilities for more responsive and outcome-driven healthcare. Read the full Arab News article: https://lnkd.in/exZFBkAw #PartexAI #ArabNews #HealthcareAI #SaudiArabia #DigitalHealth #RealWorldData #HealthcareInnovation #LifeSciences #AI #Pharma

𝗔𝗻 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝗳𝘂𝗹 𝗰𝗼𝗻𝘃𝗲𝗿𝘀𝗮𝘁𝗶𝗼𝗻 𝗼𝗻 𝘁𝗵𝗲 𝗳𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗶𝗻 𝘁𝗵𝗲 𝗞𝗶𝗻𝗴𝗱𝗼𝗺. 🇸🇦 𝗗𝗿. Gunjan Bhardwaj, Founder & CEO of Partex.AI N.V., was pleased to participate in the 𝗙𝗼𝗿𝗯𝗲𝘀 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗦𝘂𝗺𝗺𝗶𝘁 𝟮𝟬𝟮𝟲 𝗶𝗻 𝗥𝗶𝘆𝗮𝗱𝗵 as part of the panel discussion, “𝗙𝗿𝗼𝗺 𝗠𝗮𝗿𝗸𝗲𝘁 𝘁𝗼 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 – 𝗘𝘅𝗽𝗮𝗻𝗱𝗶𝗻𝗴 𝘁𝗵𝗲 𝗞𝗶𝗻𝗴𝗱𝗼𝗺’𝘀 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗙𝗼𝗼𝘁𝗽𝗿𝗶𝗻𝘁.” The discussion explored the opportunities and challenges shaping the Kingdom’s pharmaceutical ecosystem 𝗳𝗿𝗼𝗺 𝗹𝗼𝗰𝗮𝗹𝗶𝘀𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗮𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗺𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝘁𝗼 𝗥&𝗗 𝗰𝗮𝗽𝗮𝗯𝗶𝗹𝗶𝘁𝗶𝗲𝘀, 𝗿𝗲𝘀𝗶𝗹𝗶𝗲𝗻𝘁 𝘀𝘂𝗽𝗽𝗹𝘆 𝗰𝗵𝗮𝗶𝗻𝘀 𝗮𝗻𝗱 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽𝘀. Dr. Gunjan shared the stage with Ismail Shehada, CEO of Tabuk Pharmaceuticals Manufacturing Company, and Mohamed Mazen Batterjee, Managing Director of Batterjee Pharma, with 𝗥𝗲𝗵𝗮𝗻 𝗔𝗵𝗺𝗲𝗱, Acting CEO of Arabio - Arab Company for Pharmaceutical Products, moderating the discussion. As Saudi Arabia continues to strengthen its position as a regional pharmaceutical and healthcare hub, conversations like these are important in exploring how innovation, technology and collaboration can help accelerate the next phase of growth. Thank you to Forbes Middle East for bringing together leaders from across the healthcare and pharmaceutical ecosystem for this important conversation. #ForbesHealthcareSummit #PartexAI #SaudiArabia #Pharmaceuticals #Healthcare #PharmaInnovation #LifeSciences #Innovation #RAndD

𝗔𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗔𝗜 𝗮𝗻𝗱 𝗗𝗶𝗴𝗶𝘁𝗮𝗹 𝗧𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗼𝗻 𝗶𝗻 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 & 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹𝘀 🇺🇿🤝🇮🇳 Partex.AI is pleased to announce the signing of a Memorandum of Understanding (MoU) with the Medical and Pharmaceutical Industry Development Agency, Ministry of Health, Republic of Uzbekistan, following a meeting between 𝗔𝗯𝗱𝘂𝗹𝗹𝗮 𝗔𝘇𝗶𝘇𝗼𝘃, 𝗖𝗵𝗮𝗶𝗿𝗺𝗮𝗻 𝗼𝗳 𝘁𝗵𝗲 𝗔𝗴𝗲𝗻𝗰𝘆, and Dr. Gunjan Bhardwaj, Co-Founder & CEO of Partex.AI. The discussions focused on the potential of 𝗔𝗿𝘁𝗶𝗳𝗶𝗰𝗶𝗮𝗹 𝗜𝗻𝘁𝗲𝗹𝗹𝗶𝗴𝗲𝗻𝗰𝗲 𝗮𝗻𝗱 𝗱𝗶𝗴𝗶𝘁𝗮𝗹 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝗶𝗲𝘀 to strengthen pharmaceutical and healthcare systems, with particular emphasis on data management, digital infrastructure, and the integration of AI into existing healthcare platforms. As initial areas of collaboration, the two organisations explored opportunities in 𝗽𝗲𝗱𝗶𝗮𝘁𝗿𝗶𝗰 𝗼𝗻𝗰𝗼𝗹𝗼𝗴𝘆 and the development of digital infrastructure for healthcare institutions. Discussions also covered the potential to engage 𝗶𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗳𝗶𝗻𝗮𝗻𝗰𝗶𝗮𝗹 𝗶𝗻𝘀𝘁𝗶𝘁𝘂𝘁𝗶𝗼𝗻𝘀 𝗮𝗻𝗱 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀 to support the implementation and scaling of digital healthcare initiatives. The MoU establishes a foundation for continued collaboration in 𝗔𝗜, 𝗱𝗶𝗴𝗶𝘁𝗮𝗹𝗶𝘀𝗮𝘁𝗶𝗼𝗻, 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆, with the shared goal of developing solutions that can create meaningful impact across the healthcare ecosystem. We look forward to building on this partnership and working together to translate technology and innovation into tangible outcomes for healthcare. #PartexAI #ArtificialIntelligence #AI #DigitalTransformation #Healthcare #Pharmaceuticals #HealthTech #DigitalHealth #Uzbekistan #Innovation #Partnership